Clinical trial NCT01542047 (phase 1, status: terminated)
Conditions: cancer, metastatic
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: carboplatin, pazopanib
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    low rate of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Histologically confirmed advanced solid tumor type that is FDA approved for treatment
             with Carboplatin.

          -  Life expectancy at least 12 wks

          -  ECOG performance status of 0-2

          -  Provide written informed

          -  Adequate organ system function

        FEMALES:

          -  Non-childbearing potential, who has had:

          -  A hysterectomy

          -  A bilateral oophorectomy (ovariectomy)

          -  A bilateral tubal ligation

          -  Is post-menopausal

          -  Complete abstinence from sexual intercourse 14 days before, during and at least 21
             days after the last dose of investigational product

          -  Oral contraceptive

          -  Injectable progestogen

          -  Implants of levonorgestrel

          -  Estrogenic vaginal ring

          -  Percutaneous contraceptive patches

          -  Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate
             of less than 1% per year

          -  Sole male partner sterilization prior to the female subject's entry - Double barrier
             method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal
             spermicidal agent (foam/ gel/ film/cream/suppository)

          -  If lactating: discontinue nursing prior to the first dose, during and for 14 days
             following the last dose of study drug

        Exclusion Criteria:

          -  History or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
             metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure
             medication for 6 months prior to first dose of study drug.

          -  Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance
             imaging [MRI]) is required only if clinically indicated or if the subject has a
             history of CNS metastases.

          -  Clinically significant gastrointestinal abnormalities that may increase the risk for
             gastrointestinal bleeding including, but not limited to:

          -  Active peptic ulcer disease

          -  Known intraluminal metastatic lesion/s with risk of bleeding

          -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or

          -  other gastrointestinal conditions with increased risk of perforation

          -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess
             within 28 days prior to beginning study treatment

          -  Clinically significant gastrointestinal abnormalities that may affect absorption of
             investigational product including, but not limited to:

          -  Malabsorption syndrome

          -  Major resection of the stomach or small bowel.

          -  Presence of uncontrolled infection

          -  Corrected QT interval (QTc) > 480 msecs using Bazett's formula

          -  History of any one or more of the following cardiovascular conditions within the past
             6 months:

          -  Cardiac angioplasty or stenting

          -  Myocardial infarction

          -  Unstable angina

          -  Coronary artery bypass graft surgery

          -  Symptomatic peripheral vascular disease

          -  Class III or IV congestive heart failure, as defined by the New York Heart Association
             (NYHA)

          -  Poorly controlled hypertension [defined as systolic blood pressure (SBP) of greater
             than or equal to 140 mmHg or diastolic blood pressure (DBP) of greater than or equal
             to 90mmHg]

        Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to
        study entry.

          -  History of cerebrovascular accident including transient ischemic attack (TIA),
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
             Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating
             agents for at least 6 weeks are eligible

          -  Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
             presence of any non-healing wound, fracture, or ulcer (procedures such as catheter
             placement not considered to be major)

          -  Evidence of active bleeding or bleeding diathesis

          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

          -  Hemoptysis within 8 weeks of first dose of study drug

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
             could interfere with subject's safety, provision of informed consent, or compliance
             with study procedures

          -  Treatment with any of the following anti-cancer therapies:

          -  Radiation therapy, surgery or tumor embolization within 14 days prior to the first
             dose of pazopanib OR

          -  Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal
             therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the
             first dose of pazopanib

          -  Any ongoing toxicity from prior anti-cancer therapy that is greater than Grade 1
             and/or that is progressing in severity, except alopecia